A Feb. 21 Personalized Medicine Coalition report says 12 personalized treatments and seven diagnostics approved or cleared by FDA in 2019 will improve patient care and address root causes of rare diseases, expand treatment for cancer patients, and target therapies to people who respond.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
